[Comment] KEYNOTE-006: a success in melanoma, but a long way to go

A breakthrough in cancer therapy was achieved by the introduction of immune checkpoint inhibition, starting with the US Food and Drug Administration approval of the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)-specific antibody ipilimumab in 2011.1,2 Since then, clinical experience indicates that only around 20% of patients with late-stage melanoma experience durable responses with ipilimumab, but can pay a high price in terms of adverse events, because ipilimumab has been associated with autoimmune reactions like colitis that can require treatment discontinuation.
Source: LANCET - Category: General Medicine Authors: Tags: Comment Source Type: research